Free Claim Review
Time is very limited to file.
Submit the form to speak with our team.
OVARIAN CANCER & TUMOR CLAIM HELP
OVARIAN CANCER & TUMORS LINKED
CONTACT US TODAY
Filing a talcum powder claim may be the only way to hold Johnson & Johnson accountable and obtain fair compensation for medical bills, lost wages, and damages allegedly resulting from its conduct. File now before its too late.
Free Claim Review. We are here to listen and help.
Were you diagnosed with cancer following long-term use of Johnson & Johnson’s Baby Powder or Shower-to-Shower talcum powder products?
You’re not alone. Thousands of claims are already pending in courts around the United States alleging a link between the extended use of Johnson & Johnson talcum powders and various cancers, including ovarian cancer and mesothelioma. The company has also suffered multiple legal defeats in court, with jury awards totaling as much as $100 million in damages.
OVARIAN CANCER
OVARIAN TUMORS
PRIMARY PERITONEAL CANCER
FALLOPIAN TUBE CANCER
MESOTHELIOMA
Epithelial ovarian cancer is the most common type of ovarian cancer, representing about 90% of all ovarian tumors. This cancer type originates in the outer layer of cells that cover the ovary and includes different subtypes, such as serous, endometrioid, mucinous, and clear cell.
Borderline ovarian tumors are not cancerous but are characterized by abnormal cell growth in the tissue covering the ovary. While they are not as common as epithelial ovarian cancer, they still make up a significant portion of ovarian tumors.
According to the American Cancer Society, about 10% to 15% of ovarian tumors are borderline tumors. Surgical removal is typically the primary treatment for borderline ovarian tumors and often results in a complete cure.
Many pursuing Johnson & Johnson with talcum powder lawsuits claim the manufacturer knew its talc was carcinogenic, potentially contaminated by asbestos, and could cause all these cancer types but did nothing to warn consumers about the risk.
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES